CRP and Hs-CRP: The Dual Dimensions of Inflammation Monitoring

C-reactive protein (CRP), as a core biomarker for acute inflammation and infection, its highly sensitive variant Hs-CRP (high-sensitivity C-reactive protein) has further expanded the boundaries of clinical application. The conventional CRP (with a detection range of 0.5 - 300 mg/L) focuses on the rapid Diagnosis of acute infections, postoperative complications, and sepsis, while Hs-CRP (with a detection range of 0.1 - 10 mg/L) can precisely capture low-concentration inflammatory signals, providing crucial basis for cardiovascular disease risk stratification, chronic inflammation management, and screening of sub-healthy populations. The combined application of dual-nucleus detection achieves comprehensive coverage from critical emergency treatment to early prevention.

Evidence-based clinical application scenarios

1. Precise Diagnosis and Stratification of Infectious Diseases

Cooperative Detection of CRP + PCT: When CRP ≥ 50 mg/L is combined with PCT ≥ 0.5 ng/mL, it indicates bacterial infection (specificity > 95%);

Distinguishing Viral Infections: When CRP is slightly elevated (10 - 40 mg/L) and PCT is normal, viral infection or non-infectious inflammation should be considered as the priority.

2. Risk Assessment of Cardiovascular Diseases

Monitoring of Chronic Inflammation: CRP ≥ 3 mg/L indicates systemic low-grade inflammation, which is significantly associated with the risk of atherosclerosis;

Prognosis Evaluation of Coronary Heart Disease: In patients with acute coronary syndrome, if CRP remains elevated (> 10 mg/L), it suggests an adverse prognosis and requires intensified anti-inflammatory treatment.

    3. Management of Autoimmune Diseases

Dynamic tracking of inflammatory activity: The CRP level in patients with Rheumatoid Arthritis is positively correlated with disease activity (target value: CRP < 5 mg/L);

Evaluation of therapeutic efficacy: A ≥ 50% decrease in CRP after biologic therapy indicates a good therapeutic response.

    4. Postoperative and Intensive Care

Postoperative infection warning: A delayed decrease in the peak CRP level or a persistent increase (> 100 mg/L) after surgery suggests a risk of complications;

Early identification of sepsis: CRP > 100 mg/L combined with PCT ≥ 2 ng/mL can quickly initiate anti-infection treatment.

    5. Risk Stratification and Preventive Medicine for Cardiovascular Diseases

Screening of asymptomatic individuals: Hs-CRP ≥ 2 mg/L indicates a doubling of the risk of cardiovascular events. Combined with the lipid profile (such as LDL-C), it can optimize the risk prediction model (as recommended by the ACC/AHA guidelines);

Evaluation of intervention effect: After statin treatment, Hs-CRP is reduced to < 1 mg/L, indicating effective anti-inflammatory treatment and a slower progression of atherosclerosis.

For people the diagnosis of inflammatory disease and CVD assessment cutoffs have been recommended. As follows:

6. Management of Chronic Metabolic Diseases

Diabetes Complication Warning: Persistent elevation of Hs-CRP (> 3 mg/L) in patients with type 2 diabetes indicates the risk of microvascular and cardiovascular renal complications, requiring intensified comprehensive management;

Monitoring of Obesity-Related Inflammation: The level of Hs-CRP is positively correlated with visceral fat accumulation, providing a quantitative basis for lifestyle intervention.

7. Precision Diagnosis and Treatment of Autoimmune Diseases

Identification of subclinical inflammation: The detection of Hs-CRP can help identify extrarenal lesions (such as cardiovascular involvement) in patients with rheumatoid arthritis at an early stage, guiding multidisciplinary combined treatment;

Dynamic adjustment of treatment goals: Under the combined treatment with biologics, an Hs-CRP level of less than 1 mg/L can be used as a reference threshold for complete inflammation relief.

Lamuno (Fluorescence immunoassay platform): CRP/Hs-CRP dual mode, setting a new industry standard

Dual-core detection with flexible switching: The same platform supports both conventional CRP (acute phase) and Hs-CRP (chronic phase) tests. Just by switching the reagent cards, results can be simultaneously output within 15 minutes, meeting diverse clinical needs.
Super precision performance guarantee: The sensitivity of Hs-CRP reaches 0.5 mg/L, accurately identifying low-concentration inflammatory signals;

Linear range: CRP 0.5-200 mg/L, seamlessly connecting emergency and chronic disease management scenarios.

Compact design: Suitable for various application scenarios.

From Emergency Treatment to Prevention: Redefining Inflammation Management

Lamuno integrates dual detection of CRP and Hs-CRP, breaking through the limitations of traditional inflammation monitoring. In emergency scenarios, it quickly identifies the source of infection and guides the use of antibiotics; in the field of chronic diseases, it predicts cardiovascular events 10 years in advance, promoting the implementation of "preventing disease before it occurs". This innovation not only improves the efficiency of resource allocation in healthcare but also empowers patients' lifelong health management through precise data, providing technological support for the public health prevention and control system.